BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27276707)

  • 21. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease.
    Sweetenham JW
    Hematology Am Soc Hematol Educ Program; 2005; ():252-9. PubMed ID: 16304389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.
    Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N
    Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
    Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.
    Taskinen M; Louhimo R; Koivula S; Chen P; Rantanen V; Holte H; Delabie J; Karjalainen-Lindsberg ML; Björkholm M; Fluge Ø; Pedersen LM; Fjordén K; Jerkeman M; Eriksson M; Hautaniemi S; Leppä S
    PLoS One; 2014; 9(3):e91031. PubMed ID: 24625556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
    Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
    J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
    Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
    Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
    Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
    J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.
    Sebastián E; Alcoceba M; Martín-García D; Blanco Ó; Sanchez-Barba M; Balanzategui A; Marín L; Montes-Moreno S; González-Barca E; Pardal E; Jiménez C; García-Álvarez M; Clot G; Carracedo Á; Gutiérrez NC; Sarasquete ME; Chillón C; Corral R; Prieto-Conde MI; Caballero MD; Salaverria I; García-Sanz R; González M
    Ann Hematol; 2016 Jan; 95(2):253-62. PubMed ID: 26573278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma.
    Atanaskovic L; Cikota-Aleksic B; Tarabar O; Trimcev J; Zivanovic-Ivic A; Marjanovic S; Magic Z
    J BUON; 2016; 21(6):1459-1465. PubMed ID: 28039708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
    Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma.
    Saez AI; García-Cosío M; Sáez AJ; Hernández JM; Sánchez-Verde L; Alvarez D; de la Cueva P; Arranz R; Conde E; Grande C; Rodríguez J; Caballero D; Piris MA
    Leuk Lymphoma; 2009 Apr; 50(4):571-81. PubMed ID: 19373655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma.
    Kwee I; Capello D; Rinaldi A; Rancoita PM; Bhagat G; Greiner TC; Spina M; Gloghini A; Chan WC; Paulli M; Zucca E; Tirelli U; Carbone A; Gaidano G; Bertoni F
    Leuk Lymphoma; 2012 Jan; 53(1):71-6. PubMed ID: 21787262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Copy number variations are progressively associated with the pathogenesis of colorectal cancer in ulcerative colitis.
    Shivakumar BM; Rotti H; Vasudevan TG; Balakrishnan A; Chakrabarty S; Bhat G; Rao L; Pai CG; Satyamoorthy K
    World J Gastroenterol; 2015 Jan; 21(2):616-22. PubMed ID: 25605985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.